About Tocagen (NASDAQ:TOCA)
Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:TOCA
- CUSIP: N/A
- Web: www.tocagen.com
- Debt-to-Equity Ratio: 0.07%
- Current Ratio: 6.03%
- Quick Ratio: 6.03%
Sales & Book Value:
- Annual Sales: $40,000.00
- Price / Sales: 5,006.98
- Book Value: $4.04 per share
- Price / Book: 2.50
- Net Income: $-33,470,000.00
- Net Margins: -89,078.05%
- Return on Assets: -51.70%
- Employees: 61
- Outstanding Shares: 19,810,000
Frequently Asked Questions for Tocagen (NASDAQ:TOCA)
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) released its earnings results on Wednesday, November, 8th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. View Tocagen's Earnings History.
When will Tocagen make its next earnings announcement?
Where is Tocagen's stock going? Where will Tocagen's stock price be in 2017?
2 brokers have issued 12-month price targets for Tocagen's shares. Their predictions range from $19.00 to $28.00. On average, they anticipate Tocagen's stock price to reach $23.67 in the next year. View Analyst Ratings for Tocagen.
Are investors shorting Tocagen?
Tocagen saw a decrease in short interest in the month of October. As of October 13th, there was short interest totalling 490,006 shares, a decrease of 37.5% from the September 29th total of 783,892 shares. Based on an average trading volume of 125,307 shares, the days-to-cover ratio is presently 3.9 days. Currently, 2.9% of the shares of the company are short sold.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include ObsEva SA (OBSV), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals Holdings (CRBP), NantKwest (NK), Mersana Therapeutics (MRSN), Calithera Biosciences (CALA), Insys Therapeutics (INSY), Seres Therapeutics (MCRB), CymaBay Therapeutics (CBAY), Stemline Therapeutics (STML), Mast Therapeutics (SVRA), AVEO Pharmaceuticals (AVEO), NuCana PLC Sponsored ADR (NCNA), MannKind Corporation (MNKD), Merus N.V. (MRUS), Bellicum Pharmaceuticals (BLCM), Biotie Therapies Corp (BITI) and BioTime (BTX).
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Faheem Hasnain, Independent Chairman of the Board (Age 58)
- Martin J. Duvall, Chief Executive Officer, Director (Age 54)
- Mark G. Foletta CPA, Chief Financial Officer, Executive Vice President (Age 55)
- Harry E. Gruber M.D., President - Science and Innovation, Director (Age 64)
- Dennis N. Berman, Executive Vice President - Corporate Development (Age 65)
- Douglas Jolly Ph.D., Executive Vice President - Research and Pharmaceutical Development (Age 69)
- Asha Das M.D., Senior Vice President, Chief Medical Officer (Age 52)
- Thomas E. Darcy, Director (Age 66)
- Franklin M. Berger, Independent Director (Age 67)
- Lori A. Kunkel M.D., Independent Director (Age 59)
When did Tocagen IPO?
(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.
When did the company's lock-up period expire?
Tocagen's lock-up period expired on Tuesday, October 10th. Tocagen had issued 8,500,000 shares in its public offering on April 13th. The total size of the offering was $85,000,000 based on an initial share price of $10.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who owns Tocagen stock?
Tocagen's stock is owned by many different of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (3.18%), Nicholas Investment Partners LP (0.25%), Granahan Investment Management Inc. MA (0.16%) and BBR Partners LLC (0.07%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.
Who sold Tocagen stock? Who is selling Tocagen stock?
Who bought Tocagen stock? Who is buying Tocagen stock?
Tocagen's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Granahan Investment Management Inc. MA and BBR Partners LLC. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.
How do I buy Tocagen stock?
Shares of Tocagen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of Tocagen stock can currently be purchased for approximately $10.11.
How big of a company is Tocagen?
Tocagen has a market capitalization of $201.66 million and generates $40,000.00 in revenue each year. Tocagen employs 61 workers across the globe.
How can I contact Tocagen?
Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (TOCA)MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Tocagen (NASDAQ:TOCA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$23.67 (134.09% upside)|
Consensus Price Target History for Tocagen (NASDAQ:TOCA)
Analysts' Ratings History for Tocagen (NASDAQ:TOCA)
(Data available from 11/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/25/2017||Stifel Nicolaus||Reiterated Rating||Buy||$24.00||Low|
|5/15/2017||Leerink Swann||Initiated Coverage||Mkt Perform||$19.00||Medium|
|5/9/2017||Evercore ISI||Reiterated Rating||Outperform||$28.00||Low|
Earnings History and Estimates Chart for Tocagen (NASDAQ:TOCA)
Earnings History by Quarter for Tocagen (NASDAQ TOCA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/14/2018|| || || || || || || || |
|11/8/2017||Q3 2017||($0.48)||($0.50)||$0.01 million||$0.01 million||View||N/A|
|8/9/2017||Q2||($0.52)||($0.56)||$0.01 million||$0.01 million||View||N/A|
|5/23/2017||Q1 2017||($2.70)||($4.11)||$0.01 million||$0.01 million||View||N/A|
Earnings Estimates for Tocagen (NASDAQ:TOCA)
2017 EPS Consensus Estimate: ($6.89)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Tocagen (NASDAQ:TOCA)
No dividend announcements for this company have been tracked by MarketBeat.com
Latest Headlines for Tocagen (NASDAQ TOCA)
Tocagen (NASDAQ TOCA) Chart for Wednesday, November, 22, 2017